This document has been translated from the Japanese original for reference purposes only. In the eventof any discrepancy between this translated document and the Japanese original, the original shallprevail. The Company assumes no responsibility for this translation or for direct, indirect or any otherforms of damages arising from the translation.
[Cover][Document to be submitted]

Extraordinary Report (“Rinji Hokokusho”)[Submitted to]

Director-General of the Kanto Local Finance Bureau[Submission date]June 30, 2022

[Company name]

Kyorin Holdings Kabushiki Kaisha[Company name in English]

KYORIN Holdings, Inc.

[Title and name of representative]

Yutaka Ogihara
Representative Director, President and Chief Executive Officer[Location of head office]6, Kanda Surugadai 4-Chome, Chiyoda-ku, Tokyo, Japan[Telephone number]

03-3525-4700 (switchboard)[Name of contact person]

Yoh ItoSenior Corporate Officer, Director, Finance & Accounting[Nearest contact address]

6, Kanda Surugadai 4-Chome, Chiyoda-ku, Tokyo, Japan[Telephone number]

03-3525-4701[Name of contact person]

Yoh ItoSenior Corporate Officer, Director, Finance & Accounting[Place for public inspection]

Tokyo Stock Exchange, Inc.
(2-1 Nihombashi Kabutocho, Chuo-ku, Tokyo, Japan)

1. [Reason for submission]
As the proposals to be resolved at the 64th Annual General Shareholders Meeting (the “Meeting”) held on
June 24, 2022 were resolved, we hereby submit this Extraordinary Report pursuant to the provisions ofArticle 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and Article 19, Paragraph 2, Item
9-2 of the Cabinet Office Order on Disclosure of Corporate Affairs.
2. [Details of report](1) Date the Meeting was held
June 24, 2022
(2) Details of resolutions
Proposal 1: Partial Amendments to the Articles of Incorporation
The change of the Company’s trade name to KYORIN Pharmaceutical Co., Ltd. as well as thenecessary amendments to the purpose of its Articles of Incorporation, the introduction of the systemfor electronic provision of materials for general meetings of shareholders, and the maximum numberof Directors.
Proposal 2: Reduction of Legal Capital Surplus
The reduction of the amount of legal capital surplus by 30,000,000,000 yen and the transfer of thatamount to the Company’s other capital surplus.
Proposal 3: Election of Nine Directors
The election of Minoru Hogawa, Yutaka Ogihara, Shigeru Ogihara, Michiro Onota, KoichiroHagihara, Morio Yanagishima, Noriyuki Shikanai, Ken Shigematsu and Hiromi Watanabe asDirectors.
Proposal 4: Election of Four Audit & Supervisory Board Members
The election of Tomiharu Matsumoto, Kenji Akutsu, Yukio Ikemura and Kensuke Morita as Audit &Supervisory Board Members.
(3) Number of voting rights cast in approval, disapproval or declared abstained, conditions for matters to
be resolved to be approved and results of the resolutions

Proposal 1Approval(Units)
500,496

Disapproval(Units)
544

Abstention(Units)0

Proposal 2

500,1678720

Matters to be resolved

Proposal 3

Condition
for approval(Note 1)Result of resolution(Ratio of approval)
Approved (99.89%)(Note 2)

Approved (99.82%)(Note 3)

Minoru Hogawa

471,489

20,356

9,194

Approved (94.10%)

Yutaka Ogihara

480,503

20,5360

Approved (95.90%)

Shigeru Ogihara

498,5442,4960Approved (99.50%)

Michiro Onota

498,6202,4200Approved (99.51%)

Koichiro Hagihara

498,5022,5380Approved (99.49%)

Morio Yanagishima

498,650

2,3900Approved (99.52%)

Noriyuki Shikanai

498,0243,016

0Approved (99.39%)

Ken Shigematsu

498,0123,0280Approved (99.39%)

Hiromi Watanabe

498,030

3,010

Approved (99.39%)0Proposal 4(Note 3)

Tomiharu Matsumoto

486,314

14,592

127

Approved (97.06%)

Kenji Akutsu

486,308

14,598127

Approved (97.06%)

Yukio Ikemura

410,174

90,731

127

Approved (81.86%)

Kensuke Morita

500,026

1,007

0

Approved (99.79%)

Notes: 1. Attendance of shareholders representing one-third or more of the number of voting rights ofshareholders entitled to vote, and two-thirds or more of voting rights cast in approval by suchshareholders are required.
2. A majority of voting rights cast in approval by shareholders in attendance who are entitled to voteare required.
3.Attendance of shareholders representing one-third or more of the number of voting rights ofshareholders entitled to vote, and a majority of voting rights cast in approval by such shareholders
are required.
(4) Reason for excluding some units of voting rights cast by shareholders attending the Meeting from thesum of voting rights
We have excluded from the sum of voting rights a number of voting rights for which approval,
disapproval or abstention have not been confirmed cast by shareholders who attended the Meeting,because the conditions for approval of the proposals have been satisfied and the resolutions were
established in compliance with the Companies Act as a result of tallying voting rights confirmed to be
cast in approval or disapproval among those exercised in advance up to the day preceding the day of
the Meeting and those exercised by some of the attending shareholders.